SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. HEPATOLOGY 2007; 46: 922-938.
  • 2
    Sarin SK, Kumar A, Angus PW, Baijal SS, Baik SK, Bayraktar Y, et al. Asian Pacific Association for the Study of the Liver (APASL) Working Party on Portal Hypertension. Diagnosis and management of acute variceal bleeding: Asian Pacific Association for Study of the Liver recommendations. Hepatol Int 2011; 5: 607-624.
  • 3
    de Franchis R, Baveno V. Faculty revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53: 762-768.
  • 4
    Garcia-Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding—unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference. HEPATOLOGY 2008; 47: 1764-1772.
  • 5
    Sharma P, Agrawal A, Sharma BC, Sarin SK. Prophylaxis of Hepatic Encephalopathy in Acute Variceal Bleed: A Randomized Controlled Trial of Lactulose Versus no Lactulose. J Gastroenterol Hepatol 2011; 26: 996-1003.
  • 6
    D'Amico G, Pagliaro L, Pietrosi G, Tarantino I. Emergency sclerotherapy versus vasoactive drugs for bleeding oesophageal varices in cirrhotic patients. Cochrane Database Syst Rev 2010; 3: CD002233.
  • 7
    Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-236.
  • 8
    Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. A consensus workshop of the international ascites club. Gut 2007; 56: 1310-1318.
  • 9
    Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. HEPATOLOGY 2008; 48: 2064-2077.
  • 10
    Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol 2008; 48( Suppl 1): S93-S103.
  • 11
    Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. HEPATOLOGY 2006; 43: 385-394.
  • 12
    Gluud LL, Kjaer MS, Christensen E. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev 2006 4: CD005162.
  • 13
    Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. HEPATOLOGY 2010; 51: 576-584.
  • 14
    Moller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen F. Central and systemic hemodynamic effects of terlipressin in portal hypertensive patients. Liver 2000; 20: 51-59.
  • 15
    Narahara Y, Kanazawa H, Taki Y, Kimura Y, Atsukawa M, Katakura T, et al. Effects of Terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. J Gastroenterol Hepatol 2009; 24: 1791-1797.
  • 16
    Krag A, Hobolth L, Møller S, Bendtsen F. Hyponatraemia during terlipressin therapy. Gut 2010; 59: 417-418.
  • 17
    Solanski P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003; 18: 152-156.
  • 18
    Ortega R, Gines P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. HEPATOLOGY 2002; 35: 941-948.
  • 19
    Sanyal A, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al. A randomized prospective double-blind placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360-1368.
  • 20
    Martin-Llahi M, Pepin MN, Guevara M, Díaz F, Torre A, Monescillo A, et al. Terlipressin and albumin versus albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134: 1352-1359.
  • 21
    Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 2008; 103: 1689-1697.
    Direct Link:
  • 22
    Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. HEPATOLOGY 2008; 48: 2064-2077.
  • 23
    Sharma P, Singh S, Sarin SK. Hyponatremia in patients with acute variceal bleeding treated with terlipressin. HEPATOLOGY 2011; 53: 714-715.
  • 24
    Solà E, Lens S, Guevara M, Martín-Llahí M, Fagundes C, Pereira G, et al. Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. HEPATOLOGY 2010; 52: 1783-1790.
  • 25
    Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. HEPATOLOGY 2006; 43: 385-394.
  • 26
    Nazar A, Pereira GH, Guevara M, Martín-Llahi M, Pepin MN, Marinelli M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. HEPATOLOGY 2010; 51: 219-226.
  • 27
    Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol 2010 [Epub ahead of print].
  • 28
    Piano S, Morando F, Fasolato S, Cavallin M, Boscato N, Boccagni P, et al. Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation? J Hepatol 2011 [Epub ahead of print].
  • 29
    Gerbes AL, Huber E, Gülberg V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to intravenous bolus administration. Gastroenterology 2009; 137: 1179.